Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) of >6 months
- Martin Bögemann (Contributor)
- Neal Shore (Contributor)
- Tammela, T. (Contributor)
- Albertas Ulys (Contributor)
- Egils Vjaters (Contributor)
- Sergey Polyakov (Contributor)
- Mindaugas Jievaltas (Contributor)
- Murilo Luz (Contributor)
- Boris Alekseev (Contributor)
- Iris Kuss (Contributor)
- Marie-Aude Le Berre (Contributor)
- Amir Snapir (Contributor)
- Toni Sarapohja (Contributor)
- Karim Fizazi (Contributor)
Activity: Talk or presentation › Conference presentation